Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30981379 | 1.00 | CRHBP (0.50) | CRHBPCRHR2ATMCES1CES2 | |
| SCHEMBL20474769 | 0.87 | CRHBP (0.46) | CRHBPCRHR2ATMCES1CES2 | |
| SCHEMBL7375065 | 0.85 | CRHBP (0.52) | CRHBPCRHR2ATMCES1CES2 | |
| SCHEMBL10373835 | 0.84 | ATM (0.54) | CRHBPCRHR2ATMCES1CES2 | |
| SCHEMBL7371730 | 0.84 | CRHBP (0.51) | CRHBPCRHR2ATMCES1CES2 | |
| SCHEMBL18585552 | 0.83 | FSCN1 (0.54) | CRHBPCRHR2ATMCES1ALDH1A1 | |
| SCHEMBL18585286 | 0.83 | MEN1 (0.46) | CRHBPCRHR2ATMCES1ALDH1A1 | |
| SCHEMBL20474754 | 0.82 | KMT2A (0.45) | CRHBPCRHR2ATMCES1ALDH1A1 | |
| SCHEMBL20474786 | 0.82 | ACHE (0.44) | CRHBPCRHR2ATMCES1ALDH1A1 | |
| SCHEMBL8305961 | 0.82 | ALDH1A1 (0.50) | ATMCES1CES2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336688-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-02 | — | — | US | disclosed |
| US-10336688-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20190144375-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-05-16 | — | — | US | disclosed |
| US-20190144375-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10189775-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-01-29 | — | — | US | disclosed |
| US-10189775-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180237382-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-3341357-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017037595-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-03-09 | — | — | WO | disclosed |
| US-6211242-B1 | CARDIOVASCULAR DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-0757670-B1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-01-13 | — | — | EP | disclosed |
| EP-0757670-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029152-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336688-B2 | Carbocyclic compounds as ROR gamma modulators | RORB, RORC, RORA | CRHBP 612/4885CRHR2 183/4885ATM 4824/4885 |
| US-10189775-B2 | Carbocyclic compounds as ROR gamma modulators | RORB, RORC, RORA | CRHBP 612/4885CRHR2 183/4885ATM 4824/4885 |
| US-20190144375-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORC, RORA | CRHBP 663/4885CRHR2 191/4885ATM 4841/4885 |
| US-20180237382-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORC, RORA | CRHBP 663/4885CRHR2 191/4885ATM 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.